IDEAYA Biosciences, Inc. filings document the regulatory record of a Nasdaq-listed precision oncology company developing targeted therapeutics and biomarker-directed cancer programs. Recent 8-K reports cover financial results, business updates, clinical data from the OptimUM darovasertib program, collaboration agreements involving investigational oncology assets, and Regulation FD corporate presentations.
The company’s SEC record also includes proxy materials for annual meeting governance, executive compensation and equity-plan matters. Registration and prospectus filings describe IDEAYA’s common stock, automatic shelf registration capacity, at-the-market sales arrangements and related capital-structure disclosures, alongside risk and pipeline information tied to its clinical-stage oncology portfolio.
IDEAYA Biosciences (IDYA) director Malcolm Garret Hampton received a new stock option grant on June 24, 2025. The grant consists of:
- Options to purchase 20,000 shares of common stock
- Exercise price set at $21.78 per share
- Expiration date of June 24, 2035
The options feature an accelerated vesting schedule, with 100% vesting occurring at the earlier of: (1) the first anniversary of the grant date, or (2) immediately before the next Annual Meeting, contingent on Hampton's continued board service. This grant appears to be part of the company's standard director compensation program. The transaction was reported via Form 4 filed by Hampton's attorney-in-fact, Andres Ruiz Briseno.
IDEAYA Biosciences (IDYA) director Terry J. Rosen received a stock option grant on June 24, 2025. The key details of this insider transaction include:
- Granted 20,000 stock options to purchase common stock at an exercise price of $21.78 per share
- Options will expire on June 24, 2035
- Vesting schedule: 100% vests on the earlier of: - First anniversary of grant date - Immediately before next Annual Meeting
- Vesting is contingent on continued board service
This grant represents standard non-employee director compensation and aligns the director's interests with shareholders through long-term equity ownership. The filing was submitted via attorney-in-fact Andres Ruiz Briseno on June 26, 2025.
IDEAYA Biosciences held its 2025 Annual Meeting of Stockholders on June 24, 2025, where shareholders voted on three key proposals:
- Director Elections: Jeffrey L. Stein, Ph.D. was elected with strong support (69,077,770 votes for), while Scott W. Morrison received more divided support (42,132,938 votes for, 34,900,780 withheld)
- Auditor Ratification: PricewaterhouseCoopers LLP was approved as the independent auditor for FY2025 with overwhelming support (79,645,454 votes for)
- Executive Compensation: The non-binding advisory vote on executive compensation passed but showed significant dissent (59,798,805 for vs 17,040,207 against)
Out of 87,577,550 total outstanding shares eligible to vote, the meeting saw substantial shareholder participation. The split vote on Morrison's directorship and significant opposition to executive compensation suggests some shareholder concerns about governance and compensation practices.